Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07298447 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Donidalorsen Treatment in Children With Hereditary Angioedema

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 13 → 16 locationsv10
  2. Trial sites expanded: 10 → 13 locationsv9
  3. Study sites: 8 to 10v8
  4. Start date changed from estimate of Jul 2026 to Apr 21, 2026v7
  5. Study sites: 6 to 8v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 5 to 6v5
  2. Study sites: 4 to 5v4
  3. Study sites: 3 to 4v3
  4. Trial status: Not Yet Recruiting to Recruiting Start date: Jan 2026 to Jul 2026 · Study sites: 0 to 3v2 Show 2 more changesShow less
    • Start date: Jan 2026 to Jul 2026
    • Study sites: 0 to 3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).
Trial Details
NCT Number NCT07298447
Lead Sponsor Ionis Pharmaceuticals, Inc.
Conditions Hereditary Angioedema (HAE)
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov